New drugs, new money: Surge in cancer DTC ads follows wave of I-O debuts

Oncology DTC advertising has soared in recent years, thanks to new drugs and mechanisms of action. (Syneos Health)

As more oncology treatments have flooded the market, so has cancer DTC advertising. But as the American Society of Clinical Oncology's 2018 meeting neared, Syneos Health wanted to know just how big that wave has been, so its researchers analyzed Kantar data for oncology products going back to 2008.

What they found was a big spike. The $497 million spent on oncology consumer ads last year was more than six times the $80 million spent on cancer DTC over seven previous years (2008-2014).

The percentages allocated to DTC by makers of cancer drugs saw a big jump as well. From 2008 to 2014, DTC accounted for anywhere from 1% to 7% of all their spending on oncology promotions, which include in-person detailing to physicians, meetings and events, and professional journal ads. But in 2017, DTC jumped to 39% of that spending.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Much of the increase was driven by three drugs: immunotherapies Opdivo from Bristol-Myers Squibb and Keytruda from Merck, along with Pfizer's kinase inhibitor Ibrance.

RELATED: Point and counter point as JAMA tackles the question: Are cancer-related DTC ads beneficial?

“It’s a combination of new products on the market and the types of new products on the market,” said Jason Fox, vice president of Syneos Health’s syndicated operations and service. “A lot of the spend increase is due to the investment in immunotherapies.”

The new immunotherapy mechanism helped drive oncology DTC as makers looked to get the word out about the options immuno-oncology drugs offer—and to highlight advantages such as avoiding debilitating side effects of older treatments, he said.

RELATED: Syneos Health, seeking scale in a fast-moving market, fuses ad agencies GSW and Palio

The next 18 months to two years will likely continue to see oncology DTC spending trend upward, he said. But at the same time, real-world evidence will begin to determine whether immunotherapies are as effective as they seem to be in trials, which will also determine future mass media ad spending in oncology.

“If they find that Opdivo and Keytruda aren’t as effective as they thought, obviously they probably won’t be doing mass media campaigns. They’ll likely go back to a more traditional physician advertising campaign,” Fox said. “… It’s all related to outcomes. If the drugs are successful, then sure, manufacturers will continue to do DTC.”

Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.